Breast Cancer Res Treat (2017) 165:455–465 DOI 10.1007/s10549-017-4348-8 EPIDEMIOLOGY Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens 1 2 3 4 • • • • Xi Tan Tareq Fabian Camacho Virginia T. LeBaron Leslie J. Blackhall Rajesh Balkrishnan Received: 16 May 2017 / Accepted: 16 June 2017 / Published online: 21 June 2017 Springer Science+Business Media, LLC 2017 Abstract respectively). Opioid use probabilities for those who Purpose To explore differences in opioid use across dif- switched from AI to TAM were higher than those for the ferent adjuvant endocrine therapy (AET) regimens, factors TAM-only and AI-only groups. Opioid use was also sig- associated with opioid use, and the impact of opioid use on niﬁcantly associated with AET non-adherence. Opioid overall survival in female breast cancer patients treated users had a signiﬁcantly higher risk of death (adjusted with AET. hazard ratio [HR] = 1.59, p\ 0.001). Methods This retrospective study analyzed 2006–2012 Conclusions Switching from AI to TAM was associated SEER-Medicare datasets, following patients for at least with a high likelihood of opioid use. Opioid use was sig- two years from the index date, deﬁned as the ﬁrst date they niﬁcantly associated with AET non-adherence
Breast Cancer Research and Treatment – Springer Journals
Published: Jun 21, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera